Infographic: Novartis Oncology On The Verge

Like some of the other companies that are behind in the immuno-oncology space, Novartis AG is relying on combination treatments to get it back in the game and is hoping that its strength in gene therapies will give it an advantage. The Swiss pharma knows it can't recover in the near-term, but is planning to be on top in five years.